Peripheral t cell lymphoma
Drug research and approvals for peripheral t cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 152 studies of peripheral t cell lymphoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 152
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaNCT07754890 · Phase 1 / Phase 2 · Peking Union Medical College Hospital · starts Aug 26, 2025
- Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)NCT07750886 · Not reported · Natera, Inc. · starts Jul 27, 2026
- Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell LymphomaNCT07730515 · Phase 1 / Phase 2 · Evopoint Biosciences Inc. · starts Aug 15, 2025
- Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative DiseasesNCT07727083 · Not reported · Rong Tao · starts Aug 11, 2026
- Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaNCT07691450 · Phase 1 · City of Hope Medical Center · starts Jan 3, 2027
- BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCLNCT07678229 · Phase 3 · Rong Tao · starts Aug 11, 2026
- A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma…NCT07628738 · Phase 2 · Ruijin Hospital · starts Jul 1, 2026
- Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in…NCT07624838 · Not reported · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · starts Feb 15, 2026
- An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal…NCT07598578 · Early Phase 1 · Second Affiliated Hospital of Soochow University · starts Jun 1, 2026
Approved 3
- PralatrexateDihydrofolate reductase inhibitor
- RomidepsinHistone deacetylase inhibitor
- BelinostatHistone deacetylase inhibitor
Phase 3 12 of 21
- CyclophosphamideDNA inhibitor
- PrednisoneGlucocorticoid receptor agonist
- DoxorubicinDNA topoisomerase II alpha inhibitor
- Tucidinostat
- VincristineTubulin inhibitor
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- AlemtuzumabCAMPATH-1 antigen inhibitor
- CisplatinDNA inhibitor
- Denileukin diftitoxElongation factor 2 inhibitor
- MitoxantroneDNA topoisomerase II alpha inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
Phase 2 12 of 36
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- Darinaparsin
- CytarabineDNA inhibitor
- Brentuximab vedotinTubulin inhibitor
- DuvelisibPI3-kinase p110-delta subunit inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- CarmustineGlutathione reductase inhibitor
- BendamustineDNA inhibitor
- SelinexorExportin-1 inhibitor
Phase 1 or earlier 12 of 17
- Carfilzomib26S proteasome inhibitor
- ParsaclisibPI3-kinase p110-delta subunit inhibitor
- Linperlisib
- UmbralisibPI3-kinase p110-delta subunit inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- DasatinibTyrosine-protein kinase ABL inhibitor
- VolasertibSerine/threonine-protein kinase PLK1 inhibitor
- RivoceranibVascular endothelial growth factor receptor 2 inhibitor
- ForodesinePurine nucleoside phosphorylase inhibitor
- CedazuridineCytidine deaminase inhibitor
- CamrelizumabProgrammed cell death protein 1 antagonist
- CadonilimabProgrammed cell death protein 1 inhibitor
How its trials ended
627 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 156 whose ending is known, 38% met their primary endpoint, 6% missed it and 56% stopped early.
- Ongoing18730%
- Completed, result not reported16526%
- Status unknown11919%
- Met its primary endpoint599%
- Stopped: other or unclear335%
- Stopped: enrollment or feasibility254%
- Stopped: sponsor or business decision183%
- Missed its primary endpoint102%
- Stopped: lack of efficacy51%
- Stopped: safety3<1%
- Stopped: funding3<1%
| Jun 20, 2025 | An open-label, multicenter, phase 1 trial to evaluate the safety, pharmakonetics, and anti-tumour activity of TLN-121 as a single agent and in combination with…TLN-121 / Cyclophosphamide / Lunsumio (mosunetuzumab) / Columvi (glofitamab) /… | Treeline Biosciences | Ongoing |
| Dec 4, 2024 | A phase 3, randomized, open label study to investigate the efficacy and stafety of itk inhibitor soquelitinib versus physician's choice standard of care…Soquelitinib (CPI-818) | Corvus Pharmaceuticals | Ongoing |
| Oct 30, 2024 | Phase 1b, randomized, dose optimization study to assess the anti-tumor activity, safety, and pharmacokinetics of TLN-254 in patients with relapsed or…TLN-254 | Treeline Biosciences | Ongoing |
| Mar 19, 2024 | A phase 3, randomized, open-label study comparing the efficacy and safety of the combination of beleodaq-chop or folotyn-cop to the chop regimen alone in newly…Belinostat / Pralatrexate | Acrotech Biopharma | Ongoing |
| Jun 13, 2018 | "a phase 2 study of brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (chep-bv) followed by bv consolidation in patients with…Adcetris | BC Cancer, Part of The Provincial Health Services Authority | Ongoing |
| May 24, 2016 | A phase I trial of MEDI-570 in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) follicular variant and angioimmunoblastic T-cell lymphoma…MEDI-570 / Glucovision | Princess Margaret Hospital Phase I Consortium | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA